Recent News

• 11.17.2025 - Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference
• 11.13.2025 - Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update
• 11.11.2025 - Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting
• 10.23.2025 - Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review
• 09.22.2025 - Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting
• 09.18.2025 - Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
• 09.04.2025 - Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
• 08.27.2025 - Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104

Recent Filings

• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 8-K Current report
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.13.2025 - EX-99.1 EX-99.1
• 10.23.2025 - 8-K Current report
• 10.23.2025 - EX-99.1 EX-99.1
• 09.18.2025 - 8-K Current report
• 09.18.2025 - EX-99.1 EX-99.1
• 09.12.2025 - 8-K Current report
• 08.27.2025 - EX-99.1 EX-99.1